15-Deoxy-Δ12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: Role of NF-κB and early growth response transcription factors

Journal of Immunology

Volumn 178, Issue 7, 2007, Pages 4039-4050

  Fionda, Cinzia ^a,b   Nappi, Filomena ^d   Piccoli, Mario ^a   Frati, Luigi ^a,c   Santoni, Angela ^a,b   Cippitelli, Marco ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c IRCCS NEUROMED   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 9,10 DIHYDRO 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; BAY 11 7085; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAY 10410; CELL SURFACE PROTEIN; CYCLOPENTENONE; CYCLOSPORIN A; EARLY GROWTH RESPONSE FACTOR; EARLY GROWTH RESPONSE FACTOR 2; EARLY GROWTH RESPONSE FACTOR 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONOMYCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN DERIVATIVE; PROTEIN INHIBITOR; SN 50; UNCLASSIFIED DRUG; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; DRUG DERIVATIVE; MESSENGER RNA; PROSTAGLANDIN D2;

ANIMAL CELL; ARTICLE; BONE DESTRUCTION; BONE DEVELOPMENT; DRUG MECHANISM; DRUG TARGETING; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANKL GENE; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL CULTURE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HYBRIDOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROMOTER REGION; T LYMPHOCYTE; TRANSACTIVATION;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; DOWN-REGULATION; EARLY GROWTH RESPONSE TRANSCRIPTION FACTORS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; HYBRIDOMAS; LYMPHOCYTE ACTIVATION; MICE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN D2; RANK LIGAND; RNA, MESSENGER; T-LYMPHOCYTES; TRANS-ACTIVATION (GENETICS);

EID: 33947665437     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.7.4039     Document Type: Article

References (66)

1. Theill, L. E., W. J. Boyle, and J. M. Penninger. 2002. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20: 795-823.
2. Wong, B. R., R. Josien, S. Y. Lee, B. Sauter, H. L. Li, R. M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186: 2075-2080.
3. Anderson, D. M., E. Maraskovsky, W. L. Billingsley, W. C. Dougall, M. E. Tometsko, E. R. Roux, M. C. Teepe, R. F. DuBose, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T cell growth and dendritic cell function. Nature 390: 175-179.
4. Lacey, D. L., E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
5. Roodman, G. D. 1999. Cell biology of the osteoclast. Exp. Hematol. 27: 1229-1241.
6. Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
7. Walsh, N. C., T. N. Crotti, S. R. Goldring, and E. M. Gravallese. 2005. Rheumatic diseases: the effects of inflammation on bone. Immunol. Rev. 208: 228-251.
8. Clowes, J. A., B. L. Riggs, and S. Khosla. 2005. The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 208: 207-227.
9. Tanaka, S., K. Nakamura, N. Takahasi, and T. Suda. 2005. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 208: 30-49.
10. Blair, J. M., H. Zhou, M. J. Seibel, and C. R. Dunstan. 2006. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat. Clin. Pract. Oncol. 3: E1.
11. Kong, Y. Y., U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309.
12. Kotake, S., N. Udagawa, M. Hakoda, M. Mogi, K. Yano, E. Tsuda, K. Takahashi, T. Furuya, S. Ishiyama, K. J. Kim, et al. 2001. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44: 1003-1012.
13. Teng, Y. T., H. Nguyen, X. Gao, Y. Y. Kong, R. M. Gorczynski, B. Singh, R. P. Ellen, and J. M. Penninger. 2000. Functional human T cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. Invest. 106: R59-R67.
14. Roggia, C., Y. Gao, S. Cenci, M. N. Weitzmann, G. Toraldo, G. Isaia, and R. Pacifici. 2001. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 98: 13960-13965.
15. Toraldo, G., C. Roggia, W. P. Qian, R. Pacifici, and M. N. Weitzmann. 2003. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor α from T cells. Proc. Natl. Acad. Sci. USA 100: 125-130.
16. Weitzmann, M. N., S. Cenci, L. Rifas, J. Haug, J. Dipersio, and R. Pacifici. 2001. T cell activation induces human osteoclast formation via receptor activator of nuclear factor κB ligand-dependent and -independent mechanisms. J. Bone Miner. Res. 16: 328-337.
17. Giuliani, N., S. Colla, R. Sala, M. Moroni, M. Lazzaretti, S. La Monica, S. Bonomini, M. Hojden, G. Sammarelli, S. Barille, et al. 2002. Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100: 4615-4621.
18. Colucci, S., G. Brunetti, R. Rizzi, A. Zonno, G. Mori, G. Colaianni, D. Del Prete, R. Faccio, A. Liso, S. Capalbo, et al. 2004. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104: 3722-3730.
19. Roato, I., M. Grano, G. Brunetti, S. Colucci, A. Mussa, O. Bertetto, and R. Ferracini. 2005. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J. 19: 228-230.
20. Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends Immunol. 23: 144-150.
21. Willoughby, D. A., A. R. Moore, and P. R. Colville-Nash. 2000. Cyclopentenone prostaglandins-new allies in the war on inflammation. Nat. Med. 6: 137-138.
22. 2 is a ligand for the adipocyte determination factor PPAR-γ. Cell 83: 803-812.
23. Straus, D. S., and C. K. Glass. 2001. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21: 185-210.
24. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106: 189-197.
25. 2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion injury of the gut. Br. J. Pharmacol. 140: 366-376.
26. Su, C. G., X. Wen, S. T. Bailey, W. Jiang, S. M. Rangwala, S. A. Keilbaugh, A. Flanigan, S. Murthy, M. A. Lazar, and G. D. Wu. 1999. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104: 383-389.
27. 2 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168: 2508-2515.
28. Diab, A., R. Z. Hussain, A. E. Lovett-Racke, J. A. Chavis, P. D. Drew, and M. K. Racke. 2004. Ligands for the peroxisome proliferator-activated receptor-γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148: 116-126.
29. 2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br. J. Pharmacol. 138: 678-688.
30. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82.
31. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans. 2001. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52.
32. Faveeuw, C., S. Fougeray, V. Angeli, J. Fontaine, G. Chinetti, P. Gosset, P. Delerive, C. Maliszewski, M. Capron, B. Staels, et al. 2000. Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett. 486: 261-266.
33. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. USA 97: 4844-4849.
34. 2 represses nitric oxide, TNF-α, and IL-12 production by microglial cells. J. Neuroimmunol. 115: 28-35.
35. Hortelano, S., A. Castrillo, A. M. Alvarez, and L. Bosca. 2000. Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J. Immunol. 165: 6525-6531.
36. Yang, X. Y., L. H. Wang, T. Chen, D. R. Hodge, J. H. Resau, L. DaSilva, and W. L. Farrar. 2000. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ(PPARγ) agonists. PPARγ co-association with transcription factor NFAT. J. Biol. Chem. 275: 4541-4544.
37. Cippitelli, M., C. Fionda, D. Di Bona, A. Lupo, M. Piccoli, L. Frati, and A. Santoni. 2003. The cyclopentenone-type prostaglandin 15-deoxy-Δ 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-γ-independent mechanisms. J. Immunol. 170: 4578-4592.
38. Zhang, X., M. C. Rodriguez-Galan, J. J. Subleski, J. R. Ortaldo, D. L. Hodge, J. M. Wang, O. Shimozato, D. A. Reynolds, and H. A. Young. 2004. Peroxisome proliferator-activated receptor-γ and its ligands attenuate biologic functions of human natural killer cells. Blood 104: 3276-3284.
39. Mbalaviele, G., Y. Abu-Amer, A. Meng, R. Jaiswal, S. Beck, M. F. Pittenger, M. A. Thiede, and D. R. Marshak. 2000. Activation of peroxisome proliferator-activated receptor-γ pathway inhibits osteoclast differentiation. J. Biol. Chem. 275: 14388-14393.
40. Jimi, E., and S. Ghosh. 2005. Role of nuclear factor-κB in the immune system and bone. Immunol. Rev. 208: 80-87.
41. Cippitelli, M., C. Fionda, D. Di Bona, F. Di Rosa, A. Lupo, M. Piccoli, L. Frati, and A. Santoni. 2002. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J. Immunol. 168: 1154-1166.
42. Rossi, A., G. Elia, and M. G. Santoro. 1996. 2-Cyclopenten-1-one, a new inducer of heat shock protein 70 with antiviral activity. J. Biol. Chem. 271: 32192-32196.
43. Fu, Q., R. L. Jilka, S. C. Manolagas, and C. A. O'Brien. 2002. Parathyroid hormone stimulates receptor activator of NFκB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 277: 48868-48875.
44. Fan, X., E. M. Roy, T. C. Murphy, M. S. Nanes, S. Kim, J. W. Pike, and J. Rubin. 2004. Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells. J. Cell Biochem. 93: 807-818.
45. Roccisana, J. L., N. Kawanabe, H. Kajiya, M. Koide, G. D. Roodman, and S. V. Reddy. 2004. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J. Biol Chem. 279: 10500-10507.
46. Liu, J., H. Yang, W. Liu, X. Cao, and X. Feng. 2005. Sp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor κB ligand gene in osteoblasts and bone marrow stromal cells. J. Cell. Biochem. 96: 716-727.
47. Mori, K., R. Kitazawa, T. Kondo, S. Maeda, A. Yamaguchi, and S. Kitazawa. 2006. Modulation of mouse RANKL gene expression by Runx2 and PKA pathway. J. Cell. Biochem. 98: 1629-1644.
48. Scher, J. U., and M. H. Pillinger. 2005. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin. Immunol. 114: 100-109.
49. Rossi, A., P. Kapahi, G. Natoli, T. Takahashi, Y. Chen, M. Karin, and M. G. Santoro. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403: 103-108.
50. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276: 35530-35536.
51. O'Donovan, K. J., W. G. Tourtellotte, J. Millbrandt, and J. M. Baraban. 1999. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends Neurosci. 22: 167-173.
52. Decker, E. L., C. Skerka, and P. F. Zipfel. 1998. The early growth response protein (EGR-1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells. J. Biol. Chem. 273: 26923-26930.
53. Lin, J. X., and W. J. Leonard. 1997. The immediate-early gene product Egr-1 regulates the human interleukin-2 receptor β-chain promoter through noncanonical Egr and Sp1 binding sites. Mol. Cell. Biol. 17: 3714-3722.
54. Mittelstadt, P. R., and J. D. Ashwell. 1999. Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells. J. Biol. Chem. 274: 3222-3227.
55. Mittelstadt, P. R., and J. D. Ashwell. 1998. Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression. Mol. Cell. Biol. 18: 3744-3751.
56. Droin, N. M., M. J. Pinkoski, E. Dejardin, and D. R. Green. 2003. Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol. Cell. Biol. 23: 7638-7647.
57. Parfitt, A. M. 1984. The cellular basis of bone remodeling: the quantum concept reexamined in light of recent advances in the cell biology of bone. Calcif. Tissue Int. 36(Suppl. 1): S37-S45.
58. Karsenty, G., and E. F. Wagner. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2: 389-406.
59. Ehrlich, L. A., and G. D. Roodman. 2005. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol. Rev. 208: 252-266.
60. Stellon, A. J., A. Davies, J. Compston, and R. Williams. 1985. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 89: 1078-1083.
61. Knobel, H., A. Guelar, G. Vallecillo, X. Nogues, and A. Diez. 2001. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15: 807-808.
62. Piepkorn, B., P. Kann, T. Forst, J. Andreas, A. Pfutzner, and J. Beyer. 1997. Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 29: 584-591.
63. Giuliani, N., S. Colla, and V. Rizzoli. 2004. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL). Exp. Hematol. 32: 685-691.
64. Carayol, N., J. Chen, F. Yang, T. Jin, L. Jin, D. States, and C. Y. Wang. 2006. A dominant function of IKK/NF-κB signaling in global LPS-induced gene expression. J. Biol. Chem. 281: 31142-31151.
65. Ishihara, S., M. A. Rumi, T. Okuyama, and Y. Kinoshita. 2004. Effect of prostaglandins on the regulation of tumor growth. Curr. Med. Chem. Anticancer Agents 4: 379-387.
66. 2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins. Blood 105: 1750-1758.